Gamida Cell Ltd (GMDAQ)

[midastouch017]

GAMIDA CELL (GMDA) RECEIVED ITS THIRD BUY IN A ROW

https://www.markets.co/gamida-cell-gmda-received-its-third-buy-in-a-row-5/302857/

March 9, 2021 Bryan Anderson

After Piper Sandler and Oppenheimer gave Gamida Cell (NASDAQ: GMDA) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Chad Messer maintained a Buy rating on Gamida Cell today and set a price target of $14.00. The company’s shares closed last Tuesday at $8.41.

According to TipRanks.com, Messer is a 4-star analyst with an average return of 6.6% and a 46.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Autolus Therapeutics, and Sarepta Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gamida Cell with a $19.00 average price target.